Public and patient involvement (PPI) in clinical research is the new normal, but bridging the gap between how industry and charities work isn’t always easy.
Over the last few years the effect of Brexit’s political instability on our industry has been inescapable as generic and branded manufacturers alike prepare for its impact on medicine produ
We speak to Verona Pharma’s CEO Jan-Anders Karlsson to find out how the company is looking to tackle the challenges of COPD, a surprisingly overlooked disease.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.